Dublin, April 20, 2016 -- Research and Markets has announced the addition of the "Virus Filtration Market - Global Forecast to 2020" report to their offering.
The global virus filtration market is projected to reach USD 3.25 billion by 2020 from USD 1.82 billion in 2015, at a CAGR of 12.3% between 2015 and 2020.
By product, the market includes kits and reagents, filtration systems, other products and services. Based on application segment includes biologicals, medical devices, water purification, and air purification. The biologicals segment is further classified into, vaccines and therapeutics, blood and blood products, cellular and gene therapy products, tissue and tissue products and stem cell products.
The end user segments included in this report are pharmaceutical & biotechnology companies, contract research organizations, academic research institutes and medical devices companies. The pharmaceutical & biotechnology companies segment is expected to hold the largest share of the virus filtration market in 2015.
The geographic segments included in this report are North America, Europe, Asia, and Rest of the World (RoW). North America is expected to account for the largest share in the global the virus filtration market in 2015. Asia is expected to register the fastest growth during the forecast period.
The growth of this market is mainly driven by the rise in R&D expenditure, growth of biopharmaceutical industry, and increasing government support for pharmaceutical and biotechnology industry are driving factors of the virus filtration market. In addition, increasing adoption of single-use technologies is the latest trend observed in the virus filtration market.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Virus Filtration Market, By Product
7 Virus Filtration Market, By Application
8 Virus Filtration Market, By End User
9 Virus Filtration Market, By Region
10 Competitive Landscape
11 Company Profiles
Companies Mentioned:
- Asahi Kasei Medical Co.
- Charles River Laboratories International Inc.
- General Electric Company
- Lonza Group Ltd.
- Merck & Co.
- Pall Corporation
- Sartorius AG
- Sigma-Aldrich Corporation
- Thermo Fisher Scientific Inc.
- WuXi PharmaTech (Cayman) Inc.
For more information visit http://www.researchandmarkets.com/research/xsjt4d/virus_filtration
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 



